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Background
The primary objective of this study was to establish the
prognostic value of the myocardial load of PVB19 gen-
omes in patients presenting for endomyocardial biopsy
work-up of myocarditis and/or dilated cardiomyopathy
in comparison to clinical, and cardiovascular MR
parameters.
Methods
108 consecutive patients who underwent EMB because
of suspected myocarditis and/or dilated cardiomyopathy,
and had evidence of myocardial PVB19 by PCR were
enrolled. The mean follow-up was 1319 days. Primary
endpoint was all-cause mortality, secondary endpoint
was a composite of cardiac mortality and hospitalization
for heart-failure.
Results
Mean ejection fraction of all patients was 40%. We
found n=27 patients to have a viral load ≥500 GE, n=
72 had 100-499 GE and n=9 had <100 GE. Immunohis-
tology revealed chronic myocarditis in n=66 patients,
DCM in n=17, other pathologies in n=12 (including 1
acute myocarditis), and latent PVB19 in n=13. During
follow-up 11 of 108 patients died, two patients suffered
SCD but were successfully shocked by their ICD, and 21
patients were hospitalized for heart failure.
Interestingly, not the viral load, but functional para-
meters such as LV-EF, LV-EDV (for endpoint 2), as well
as the histologic diagnosis of DCM and the presence of
LGE (for all endpoints) reached statistical significance.
In fact, the presence of LGE yields an odds-ratio for a
lethal event of 8.56 (endpoint 1), and of 5.52 for end-
point 2.
Importantly, no patient with normal LV-EF, or the
absence of LGE suffered cardiac death during long-term
follow-up.
Conclusions
The viral load of PVB19 genomes in the myocardium is
not related to the long-term clinical outcome. Further-
more, this study underscores the growing role of ima-
ging parameters for risk-stratification of patients with
non-ischemic myocardial disease.
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